Company Overview
Medline Inc. operates as a leading manufacturer of medical-surgical products, servicing a diverse array of healthcare environments including hospitals, surgery centers, physician offices, post-acute facilities, and nursing homes across the United States and international markets. The company functions within the Healthcare sector, specifically in the Medical Instruments & Supplies industry, a segment defined by the provision of essential consumables and equipment required for patient care and clinical operations. This entity commands a significant market presence with a market capitalization of $35.38B and reported annual revenue of $28.43B, supported by a workforce comprising 45,000 employees. These valuation and revenue figures indicate that Medline Inc. holds a substantial position within the healthcare supply chain, reflecting its capacity to generate billions in sales while maintaining a large operational footprint. The scale of the business suggests deep integration into the global healthcare ecosystem, where consistent demand for sterile supplies and medical instruments drives the company's core operations.
Financial Health
The company reported a trailing twelve-month revenue of $28.43B, with net income of $1.16B and EBITDA of $3.19B, revealing a distinct gap between top-line revenue and bottom-line profit that highlights a cost structure involving significant operating expenses, taxes, and interest costs. Free cash flow stands at $791.25M, a metric that demonstrates the company's ability to generate cash after capital expenditures, thereby providing financial flexibility for operational investments, debt servicing, or strategic acquisitions. Profitability is characterized by a gross margin of 26.4%, an operating margin of 5.7%, and a profit margin of 4.1%, where the low operating and profit margins relative to gross margins indicate high levels of overhead, competitive pricing pressures, or significant cost of goods sold inherent to the medical supply distribution model. On the balance sheet, total debt stands at $13.01B against cash reserves of $1.98B, resulting in a debt-to-equity ratio of 67.47%, which signifies a leveraged balance sheet where liabilities significantly outweigh equity. Liquidity is robust, evidenced by a current ratio of 4.29, indicating that the company holds more than four times the current assets necessary to cover its short-term liabilities without immediate distress. Return on equity is 6.5% while return on assets is 3.7%, metrics that reveal management effectiveness in generating returns on shareholder capital and utilizing the total asset base to produce earnings.
Valuation Assessment
Valuation multiples for the stock include a trailing P/E ratio of 30.48 and a forward P/E of 26.36, where the difference between these figures implies that the market expects earnings to grow significantly over the coming year to justify the lower forward multiple. The price-to-book ratio is 3.30, indicating that the market values the company at a premium of 3.3 times its book value, suggesting investors are pricing in intangible assets, brand strength, or future growth potential beyond the tangible net worth. Alternative valuation metrics such as a price-to-sales ratio of 1.24 and an EV/EBITDA of 17.23 provide context by showing the company trades at a premium relative to its sales and earnings before interest, taxes, depreciation, and amortization, reflecting high expectations for future performance. Regarding price metrics, the 52-week high is $50.88 and the 52-week low is $34.89, and without a specific current share price provided in the source data, the exact percentage deviation cannot be calculated, but the range establishes the volatility boundaries for the security. The beta value is not available, meaning specific volatility relative to the broader market cannot be quantified for this security based on the provided facts.
Growth & Income
Revenue growth year-over-year is 14.8%, while earnings growth year-over-year is 1254.7%, indicating that earnings are growing at a vastly accelerated pace compared to revenue, which often occurs when one-time gains, cost reductions, or significant restructuring impacts inflate the bottom line disproportionately. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all net income into operations, debt reduction, or share buybacks rather than distributing cash to shareholders. This reinvestment strategy is typical for companies in the growth phase or those prioritizing balance sheet optimization over immediate income generation for investors. The overall growth and income profile is defined by strong top-line expansion and explosive earnings per share growth, coupled with a zero-dividend policy that channels capital back into the business or capital structure adjustments.